Phase I Trial of GR1803 Injection in Patients With RRMM

Clinical trial NCT07102706 · COMPLETED

Trial details

NCT number: NCT07102706
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma (MM)

Start date: 2022-05-27
Primary completion: 2025-05-20
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.